- Home
- AUPH vs ECAT Comparison
AUPH vs ECAT Comparison
Compare AUPH & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ECAT
- Stock Information
- Founded
- AUPH 1993
- ECAT 2021
- Country
- AUPH Canada
- ECAT United States
- Employees
- AUPH N/A
- ECAT N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- AUPH Health Care
- ECAT Finance
- Exchange
- AUPH Nasdaq
- ECAT Nasdaq
- Market Cap
- AUPH 1.6B
- ECAT 1.6B
- IPO Year
- AUPH 1999
- ECAT N/A
- Fundamental
- Price
- AUPH $12.54
- ECAT $16.55
- Analyst Decision
- AUPH Strong Buy
- ECAT
- Analyst Count
- AUPH 2
- ECAT 0
- Target Price
- AUPH $13.00
- ECAT N/A
- AVG Volume (30 Days)
- AUPH 1.2M
- ECAT 278.6K
- Earning Date
- AUPH 11-10-2025
- ECAT 01-01-0001
- Dividend Yield
- AUPH N/A
- ECAT 9.20%
- EPS Growth
- AUPH N/A
- ECAT N/A
- EPS
- AUPH 0.42
- ECAT 2.39
- Revenue
- AUPH $260,111,000.00
- ECAT N/A
- Revenue This Year
- AUPH $17.33
- ECAT N/A
- Revenue Next Year
- AUPH $14.31
- ECAT N/A
- P/E Ratio
- AUPH $30.05
- ECAT $7.15
- Revenue Growth
- AUPH 25.59
- ECAT N/A
- 52 Week Low
- AUPH $6.55
- ECAT $14.02
- 52 Week High
- AUPH $13.54
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- AUPH 60.86
- ECAT 57.59
- Support Level
- AUPH $11.48
- ECAT $16.02
- Resistance Level
- AUPH $12.70
- ECAT $16.70
- Average True Range (ATR)
- AUPH 0.34
- ECAT 0.19
- MACD
- AUPH 0.13
- ECAT 0.03
- Stochastic Oscillator
- AUPH 89.64
- ECAT 85.29
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.